Roche's Challenge With Herceptin Gastric Cancer Claim Will Be Companion Dx Use

As with Herceptin in breast cancer, the drug is approved simultaneously with a companion diagnostic to measure HER2 levels in gastric cancer patients, but the use of the test is different.